Last updated on April 21, 2014 at 1:20 EDT

Latest Pernix Therapeutics Stories

2012-07-10 06:27:34

THE WOODLANDS, Texas, July 10, 2012 /PRNewswire/ -- Pernix Therapeutics (NYSE: MKT: PTX), a specialty pharmaceutical company, today announced that Omeclamox-Pak(®) is now available to patients for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients. Omeclamox-Pak is a ten-day, triple combination oral therapy comprised of omeprazole delayed-release capsules (20 mg),...

2012-03-21 06:25:11

BETHLEHEM, Pa., March 21, 2012 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, today announced that it is developing with Pernix Therapeutics, a specialty pharmaceutical company, a new topical dermatology product for the pediatric market. Mark Mitchnick, CEO of Particle Sciences, said, "There are multiple treatments for many pediatric skin conditions. The unmet need is in the delivery of these agents via a more convenient, and improved vehicle. Particle...